{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T10:13:50Z","timestamp":1784628830077,"version":"3.55.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T00:00:00Z","timestamp":1624579200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.euroneuro.2021.06.003","type":"journal-article","created":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T20:53:11Z","timestamp":1625518391000},"page":"18-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Treating alcohol dependence with an abuse and misuse deterrent formulation of sodium oxybate: Results of a randomised, double-blind, placebo-controlled study"],"prefix":"10.1016","volume":"52","author":[{"given":"Julien","family":"Guiraud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Addolorato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri-Jean","family":"Aubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Batel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"de Bejczy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Caputo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna E.","family":"Goudriaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoni","family":"Gual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto","family":"Lesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Icro","family":"Maremmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Perney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roch","family":"Poulnais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quentin","family":"Raffaillac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Soderpalm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Spanagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henriette","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"van den Brink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2021.06.003_bib0001","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/jcp.0b013e31815a2542","article-title":"Relative abuse liability of \u03b3-hydroxybutyric acid, flunitrazepam, and ethanol in club drug users","volume":"27","author":"Abanades","year":"2007","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2021.06.003_bib0002","first-page":"1596","article-title":"Gamma-hydroxybutyric acid (GHB) in the treatment of alcohol withdrawal syndrome: a randomized comparative study versus benzodiazepine","volume":"23","author":"Addolorato","year":"1999","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.euroneuro.2021.06.003_bib0003","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1517\/13543780902905855","article-title":"The therapeutic potential of gamma-hydroxybutyric acid for alcohol dependence: balancing the risks and benefits. A focus on clinical data","volume":"18","author":"Addolorato","year":"2009","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.euroneuro.2021.06.003_bib0004","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/14740338.2020.1709821","article-title":"Post-marketing and clinical safety experience with sodium oxybate for the treatment of alcohol withdrawal syndrome and maintenance of abstinence in alcohol-dependent subjects","volume":"19","author":"Addolorato","year":"2020","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.euroneuro.2021.06.003_bib0005","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1530-0277.1995.tb01475.x","article-title":"The obsessive compulsive drinking scale: a self-rated instrument for the quantification of thoughts about alcohol and drinking behavior","volume":"19","author":"Anton","year":"1995","journal-title":"Alcoholism"},{"key":"10.1016\/j.euroneuro.2021.06.003_bib0006","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/01.jcp.0000172071.81258.04","article-title":"Naltrexone combined with either cognitive behavioral or motivational enhancement therapy for alcohol dependence","volume":"25","author":"Anton","year":"2005","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2021.06.003_bib0007","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1176\/ajp.156.11.1758","article-title":"Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial","volume":"156","author":"Anton","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2021.06.003_bib0008","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1590\/S1516-44462003000300007","article-title":"Efficacy of acamprosate in the treatment of alcohol-dependent outpatients","volume":"25","author":"Baltieri","year":"2003","journal-title":"Revista Brasileira de Psiquiatria"},{"key":"10.1016\/j.euroneuro.2021.06.003_bib0009","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1111\/j.1360-0443.2008.02355.x","article-title":"Comparing topiramate with naltrexone in the treatment of alcohol dependence*","volume":"103","author":"Baltieri","year":"2008","journal-title":"Addiction"},{"key":"10.1016\/j.euroneuro.2021.06.003_bib0010","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0376-8716(02)00340-X","article-title":"Gamma-hydroxybutyric acid versus naltrexone in maintaining alcohol abstinence: an open randomized comparative study","volume":"70","author":"Caputo","year":"2003","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.euroneuro.2021.06.003_bib0011","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.euroneuro.2007.04.008","article-title":"Comparing and combining gamma-hydroxybutyric acid (GHB) and naltrexone in maintaining abstinence from alcohol: an open randomised comparative study","volume":"17","author":"Caputo","year":"2007","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2021.06.003_bib0012","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s40263-014-0183-1","article-title":"Sodium oxybate in the treatment of alcohol withdrawal syndrome: a randomized double-blind comparative study versus oxazepam. The GATE 1 trial","volume":"28","author":"Caputo","year":"2014","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2021.06.003_bib0013","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/alcalc\/35.2.176","article-title":"United Kingdom multicentre acamprosate study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol","volume":"35","author":"Chick","year":"2000","journal-title":"Alcohol Alcohol."},{"key":"10.1016\/j.euroneuro.2021.06.003_bib0014","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1177\/0269881111408463","article-title":"Substitution therapy for alcoholism: time for a reappraisal?","volume":"26","author":"Chick","year":"2012","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2021.06.003_bib0015","doi-asserted-by":"crossref","unstructured":"Colombo, G., Agabio, R., Lobina, C., Faddat, F., Gessa, G.L., 1995. Symmetrical Generalization Between the Discriminative Stimulus Effects of Gamma- Hydroxybutyric Acid and Ethanol: occurrence Within Narrow Dose Ranges 7.","DOI":"10.1016\/0031-9384(94)00215-Q"},{"key":"10.1016\/j.euroneuro.2021.06.003_bib0016","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1369-1600.2000.tb00207.x","article-title":"Gamma-hydroxybutyric acid in alcohol preference, dependence and withdrawal","volume":"5","author":"Colombo","year":"2000","journal-title":"Addict. Biol."},{"key":"10.1016\/j.euroneuro.2021.06.003_bib0017","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/978-3-662-44519-8_15","article-title":"Lessons to be learned from placebo arms in psychopharmacology trials","volume":"225","author":"Doering","year":"2014","journal-title":"Handb Exp. Pharmacol."},{"key":"10.1016\/j.euroneuro.2021.06.003_bib0018","unstructured":"European Medicines Agency, 2019. Guideline on the investigation of subgroups in confirmatory clinical trials. EMA\/CHMP\/539146\/2013. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-subgroups-confirmatory-clinical-trials_en.pdf Accessed March 5, 2021."},{"key":"10.1016\/j.euroneuro.2021.06.003_bib0019","unstructured":"European Medicines Agency, 2012. Selincro - European Public Assessment Report. EMA\/78844\/20132005. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/selincro-epar-public-assessment-report_en.pdf Accessed March 5, 2021."},{"key":"10.1016\/j.euroneuro.2021.06.003_bib0020","unstructured":"European Medicines Agency, 2010. Guideline on the development of medicinal products for the treatment of alcohol dependence. EMA\/CHMP\/EWP\/20097\/2008. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-development-medicinal-products-treatment-alcohol-dependence_en.pdf Accessed March 4, 2021, a."},{"key":"10.1016\/j.euroneuro.2021.06.003_bib0021","unstructured":"European Medicines Agency, 2007. Reflection Paper on Methodological Issues in Confirmatory Clinical Trials Planned with an Adaptive Design. CHMP\/EWP\/2459\/02. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/reflection-paper-methodological-issues-confirmatory-clinical-trials-planned-adaptive-design_en.pdf Accessed March 5, 2021, b January 2021."},{"key":"10.1016\/j.euroneuro.2021.06.003_bib0022","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0140-6736(89)90842-8","article-title":"Gamma-hydroxybutyric acid for treatment of alcohol withdrawal syndrome","volume":"2","author":"Gallimberti","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2021.06.003_bib0023","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1530-0277.1992.tb00658.x","article-title":"Gamma-hydroxybutyric acid in the treatment of alcohol dependence: a double-blind study","volume":"16","author":"Gallimberti","year":"1992","journal-title":"Alcoholism"},{"key":"10.1016\/j.euroneuro.2021.06.003_bib0024","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.euroneuro.2013.02.006","article-title":"A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence","volume":"23","author":"Gual","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2021.06.003_bib0025","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.alcohol.2011.08.008","article-title":"Baseline trajectories of heavy drinking and their effects on postrandomization drinking in the COMBINE Study: empirically derived predictors of drinking outcomes during treatment","volume":"46","author":"Gueorguieva","year":"2012","journal-title":"Alcohol"},{"key":"10.1016\/j.euroneuro.2021.06.003_bib0026","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1530-0277.2010.01369.x","article-title":"Baseline trajectories of drinking moderate acamprosate and naltrexone effects in the COMBINE study","volume":"35","author":"Gueorguieva","year":"2011","journal-title":"Clin. Expe. Res."},{"key":"10.1016\/j.euroneuro.2021.06.003_bib0027","volume":"version 6.1","author":"Higgins","year":"2020"},{"key":"10.1016\/j.euroneuro.2021.06.003_bib0028","series-title":"Handbook of Clinical Alcoholism Treatment","first-page":"282","article-title":"Brief behavioral compliance enhancement treatment (BBCET) manual.","author":"Johnson","year":"2003"},{"key":"10.1016\/j.euroneuro.2021.06.003_bib0029","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1037\/a0031692","article-title":"Comparative abuse liability of GHB and ethanol in humans","volume":"21","author":"Johnson","year":"2013","journal-title":"Exp. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2021.06.003_bib0030","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s40261-013-0158-x","article-title":"Sodium oxybate: a review of its use in alcohol withdrawal syndrome and in the maintenance of abstinence in alcohol dependence","volume":"34","author":"Keating","year":"2014","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.euroneuro.2021.06.003_bib0031","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archpsyc.60.1.92","article-title":"Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study","volume":"60","author":"Kiefer","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2021.06.003_bib0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euroneuro.2019.12.117","article-title":"Placebo-to be or not to be? are there really alternatives to placebo-controlled trials?","volume":"32","author":"Krol","year":"2020","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2021.06.003_bib0033","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006266.pub2","article-title":"Gamma-hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses","author":"Leone","year":"2010","journal-title":"Cochrane Database Syst. Rev. CD006266"},{"key":"10.1016\/j.euroneuro.2021.06.003_bib0034","series-title":"Alcohol and Tobacco: Medical and Sociological Aspects of Use, Abuse and Addiction","author":"Lesch","year":"2020"},{"key":"10.1016\/j.euroneuro.2021.06.003_bib0035","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1111\/acer.12197","article-title":"The placebo effect in clinical trials for alcohol dependence: an exploratory Aanalysis of 51 naltrexone and acamprosate studies","volume":"37","author":"Litten","year":"2013","journal-title":"Alcoholism"},{"key":"10.1016\/j.euroneuro.2021.06.003_bib0036","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.biopsych.2012.10.020","article-title":"Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene","volume":"73","author":"Mann","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2021.06.003_bib0037","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/j.euroneuro.2016.10.008","article-title":"Nalmefene for the management of alcohol dependence: review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy","volume":"26","author":"Mann","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2021.06.003_bib0038","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/02791072.2001.10400478","article-title":"Long-term therapy using GHB (sodium gamma hydroxybutyrate) for treatment-resistant chronic alcoholics","volume":"33","author":"Maremmani","year":"2001","journal-title":"J. Psychoactive Drugs"},{"key":"10.1016\/j.euroneuro.2021.06.003_bib0039","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0741-8329(99)00093-2","article-title":"Gamma-hydroxybutyric acid and alcohol-related syndromes","volume":"20","author":"Moncini","year":"2000","journal-title":"Alcohol"},{"key":"10.1016\/j.euroneuro.2021.06.003_bib0040","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1080\/00952990701315046","article-title":"Gamma-hydroxybutyrate reduces both withdrawal syndrome and hypercortisolism in severe abstinent alcoholics: an open study vs. diazepam.","volume":"33","author":"Nava","year":"2007","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.euroneuro.2021.06.003_bib0041","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1177\/0269881110363315","article-title":"Review: the involvement of gamma-hydroxybutyrate in reported sexual assaults: a systematic review","volume":"24","author":"N\u00e9meth","year":"2010","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2021.06.003_bib0042","unstructured":"Nice, 2011. Alcohol-use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence - appendix 17d Pharmacological Interventions Forest Plots. b."},{"key":"10.1016\/j.euroneuro.2021.06.003_bib0043","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/FBP.0b013e32833b3397","article-title":"Behavioral effects of \u03b3-hydroxybutyrate in humans","volume":"21","author":"Oliveto","year":"2010","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.euroneuro.2021.06.003_bib0044","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1192\/bjp.171.1.73","article-title":"Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study","volume":"171","author":"Pelc","year":"1997","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2021.06.003_bib0045","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1159\/000365284","article-title":"Prevalence of and potential influencing factors for alcohol dependence in Europe","volume":"21","author":"Rehm","year":"2015","journal-title":"Eur. Addict. Res."},{"key":"10.1016\/j.euroneuro.2021.06.003_bib0046","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/j.1360-0443.2010.02899.x","article-title":"The relation between different dimensions of alcohol consumption and burden of disease: an overview","volume":"105","author":"Rehm","year":"2010","journal-title":"Addiction"},{"key":"10.1016\/j.euroneuro.2021.06.003_bib0047","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/adb.12646","article-title":"Alcohol dependence and very high risk level of alcohol consumption: a life-threatening and debilitating disease","volume":"23","author":"Rehm","year":"2018","journal-title":"Addict. Biol."},{"key":"10.1016\/j.euroneuro.2021.06.003_bib0048","series-title":"Alcohol consumption, Alcohol Dependence and Attributable Burden of Disease in Europe. Potential gains from Effective Interventions For Alcohol Dependence","author":"Rehm","year":"2012"},{"key":"10.1016\/j.euroneuro.2021.06.003_bib0049","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1093\/alcalc\/agx030","article-title":"A randomized, placebo-controlled study of high-dose baclofen in alcohol-dependent patients\u2014the ALPADIR study","volume":"52","author":"Reynaud","year":"2017","journal-title":"Alcohol Alcohol."},{"key":"10.1016\/j.euroneuro.2021.06.003_bib0050","series-title":"Alcohol Dependence Scale (ADS): User's guide","author":"Skinner","year":"1984"},{"key":"10.1016\/j.euroneuro.2021.06.003_bib0051","doi-asserted-by":"crossref","unstructured":"Sobell, L.C., Sobell, M.B., 1992. Timeline follow-back: a technique Assessing Self-Reported Alcohol Consumption 33.","DOI":"10.1007\/978-1-4612-0357-5_3"},{"key":"10.1016\/j.euroneuro.2021.06.003_bib0052","doi-asserted-by":"crossref","first-page":"105","DOI":"10.31887\/DCNS.2002.4.1\/ssonawalla","article-title":"Placebo response in depression","volume":"4","author":"Sonawalla","year":"2002","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.euroneuro.2021.06.003_bib0053","unstructured":"US Food and Drug Administration, 2019. Enrichment Strategies for Clinical Trials to Support Determination of Effectiveness of Human Drugs and Biological Products Guidance for Industry. Available at: https:\/\/www.fda.gov\/media\/121320\/download Accessed March 5, 2021 45."},{"key":"10.1016\/j.euroneuro.2021.06.003_bib0054","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/adb.12645","article-title":"Efficacy and safety of sodium oxybate in alcohol-dependent patients with a very high drinking risk level","volume":"23","author":"van den Brink","year":"2018","journal-title":"Addict. Biol."},{"key":"10.1016\/j.euroneuro.2021.06.003_bib0055","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/alcalc\/agt061","article-title":"Efficacy of as-needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: results from a subgroup analysis of two randomized controlled 6-month studies","volume":"48","author":"van den Brink","year":"2013","journal-title":"Alcohol Alcohol."},{"key":"10.1016\/j.euroneuro.2021.06.003_bib0056","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1177\/0269881114527362","article-title":"Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: a 1-year, randomised controlled study","volume":"28","author":"van den Brink","year":"2014","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2021.06.003_bib0057","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/archpsyc.1997.01830200071010","article-title":"Naltrexone and alcohol dependence. Role of subject compliance","volume":"54","author":"Volpicelli","year":"1997","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2021.06.003_bib0059","unstructured":"World Health Organization, 2000. International guide for monitoring alcohol consumption and related harm."},{"key":"10.1016\/j.euroneuro.2021.06.003_bib60","unstructured":"World Health Organization, 2018. Global status report on alcohol and health 2018. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO. http:\/\/www.who.int\/substance_abuse\/publications\/global_alcohol_report\/en\/."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X21002522?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X21002522?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T18:00:05Z","timestamp":1760378405000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X21002522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":59,"alternative-id":["S0924977X21002522"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2021.06.003","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treating alcohol dependence with an abuse and misuse deterrent formulation of sodium oxybate: Results of a randomised, double-blind, placebo-controlled study","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2021.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}